StockIQpro
NASDAQ:LEXX

Lexaria Bioscience Corp.

Track all markets on TradingView
Track all markets on TradingView

Lexaria Bioscience Corp.'s revenue grew 52.0% in fiscal 2025 to $705,923 while operating margin fell to −1683.0%. Free cash flow was −$10.5M, −1483.9% of revenue, and the diluted share count rose 45.3%.Summary generated from Lexaria Bioscience Corp.'s SEC filings. Latest annual report filed Nov 28, 2025.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$705,923
Revenue growth+52.0%
Revenue, 5-yr CAGR+17.5%
Gross margin99.6%
Operating margin−1683.0%
Net margin−1686.0%
ROICn/a
Return on equity−215.9%
Debt / equityn/a
Free cash flow−$10.5M
FCF margin−1483.9%
Share count change+45.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue10001
Operating income−6−7−7−6−12
Net income−4−7−7−6−12
Free cash flown/a−5−6−5−10

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations